Human PDE1A (GenBank Accession No. NM_005019), full length with N-terminal GST-tag, MW= 88.3 kDa, expressed in a Baculovirus infected Sf9 cell expression system.

P54750-4

PDE1A, phosphodiesterase 1A

≥ 43,000 pmol/min/µg

One unit is defined as the amount of enzyme that will convert 1 pmole of 3', 5'-cAMP to 5'-AMP per minute at 37°C.

Assayed using BPS's PDE1A Assay Kit, Cat. # 60310. Assay conditions: 10 mM Tris-HCl, pH 7.4, 10 mM MgCl₂, 0.1 mg/ml BSA, 0.05% Tween-20, 200 µM cAMP, 2.5 kU 5'-nucleotidase, and serial dilutions of PDE1A at 37°C for 20 min. Quantified by 5'- nucleotidase cleaving the 5' -AMP product and releasing the phosphate group which is detected by Malachite Green Reagent.

40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, 3 mM DTT, and 20% glycerol

Aqueous buffer solution

>6 months at -80°C.

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

1. Nagel, D.J., et al., Circ. Res. 98 (6), 777-784 (2006).
2. Goraya, T.A.., et al., J. Biol. Chem. 279 (39), 40494-40504 (2004).

Application Reference(s):
1. PDE1A inhibition elicits cGMP-dependent relaxation of rat mesenteric arteries (2017)
2. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders (2017)
3. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A (2015)
4. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance (2014)
5. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey (2013)

Avoid freeze/thaw cycles.

PDE

Recombinant Protein